Beta Bionics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Beta Bionics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-14.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 55% of Healthcare companies in United States.
Cash Locked Ratio
$37For every $100 of sales, $37 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $877 from others' credit three years earlier.
More money tied up than 76% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
−$8Sales grew 55,906% in 3 years, but profit fell: $8 less profit per $100 of extra sales.
Lower than 74% of Healthcare companies in United States.
Asset Productivity Ratio
+55906% / +825%In 3 years sales changed by +55906% while total assets changed by +825%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-26.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 61% of Healthcare companies in United States.
Cash Cushion Ratio
+20%Cash, after subtracting all debt, equals 20% of its market value (net cash).
Higher than 63% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Beta Bionics, Inc. made a loss over the last year. Beta Bionics, Inc. owes $0.12 for every $1 it owns. Beta Bionics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossBeta Bionics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
4.07The share price is 4.07 times Beta Bionics, Inc.'s book value per share, higher than 66% of Healthcare companies in United States.
Market cap
$1.0 BThe total market value of all of Beta Bionics, Inc.'s shares at today's price (share price × number of shares), larger than 64% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$256 MWhat Beta Bionics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$4.75Net worth divided by the number of shares. The share price of $19.34 is 4.1 times this, which is the P/B above.
Return on equity (ROE)
-26.2%Beta Bionics, Inc. lost 26.2% of its shareholders' money over the last year, higher than 62% of Healthcare companies in United States.
Owes vs Owns
0.12×Beta Bionics, Inc. owes $0.12 for every $1 it owns (low), lower than 83% of Healthcare companies in United States.
Dividend yield
NoneBeta Bionics, Inc. does not currently pay a dividend.
Revenue growth
+54%Revenue rose 54% in the year to Dec 2025, and grew 724% a year on average over 3 years.
Profit growth
LossBeta Bionics, Inc. made a loss in each of the last two years.
Profit margin
-73.0%Beta Bionics, Inc. lost $73 for every $100 of revenue.
Cash vs debt
Net cashBeta Bionics, Inc. held $212 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Beta Bionics, Inc.: $1.0 B ÷ $256 M (30 Jun 2026) = 4.1.
What is Beta Bionics, Inc.'s return on equity?
Beta Bionics, Inc. lost 26.2% of its shareholders' money over the last year, higher than 62% of Healthcare companies in United States.
How much does Beta Bionics, Inc. owe compared with what it owns?
Beta Bionics, Inc. owes $0.12 for every $1 it owns (low), lower than 83% of Healthcare companies in United States.
Does Beta Bionics, Inc. pay a dividend?
No. Beta Bionics, Inc. does not currently pay a dividend.
Is Beta Bionics, Inc.'s revenue growing?
Revenue rose 54% in the year to Dec 2025, and grew 724% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.